NCT00587275View on ClinicalTrials.gov

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG

AST-120

Oral, sachet, 2 grams daily for 4 weeks

DRUG

Celphere CP-305

Oral, sachet, 2 grams daily for 4 weeks

Trial Locations (1)

85723

Southern Arizona VA Health Care System and University of Arizona Health Sciences Center, Tucson

Sponsors

Lead Sponsor

Ocera Therapeutics
All Listed Sponsors
lead

Ocera Therapeutics

INDUSTRY

NCT00587275 - Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI | Biotech Hunter | Biotech Hunter